Burning Rock Biotech Ltd (BNR)

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Ticker
BNR
Exchange
Nasdaq
Sector
Healthcare
Industry
Diagnostics & Research
52-week range
$6.79 - $41.72

Valuation

Share price
$13.07 (close of Nov 18, 2026)
P/E (TTM)
-15.27x
Price to book
1.78x
Price to free cash flow
-27.17x

Price performance

PeriodChange
1 day+4.56%
5 days-1.28%
1 month+1.32%
3 months+40.39%
6 months-21.74%
Year to date-35.14%
1 year-8.67%
3 years+45.22%
5 years-91.84%
All time-94.69%

Short interest

As of
Oct 30, 2026
Short % of float
0.48%
Shares short
34.33K
Days to cover
1.34
Change since prior report
-6.95%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
-10.34%
Return on invested capital
-9.48%
Return on assets
-6.75%
Return on capital employed
-9.56%
Gross margin
74.67%
Net margin
-10.26%
EBITDA margin
-6.13%
Revenue growth
4.60%

Cash flow and balance sheet

Free cash flow yield (TTM)
-3.68%
Current ratio
3.05x
Net debt to EBITDA
13.60x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Shares outstanding
10.79M

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3174.67%-10.26%-10.34%-9.48%
2024-12-3170.26%-67.20%-59.68%-56.47%
2023-12-3167.59%-121.63%-85.07%-85.73%
2022-12-3167.47%-172.44%-83.85%-81.08%
2021-12-3171.70%-156.87%-43.17%-41.26%
2020-12-3173.02%-94.73%-16.82%-16.98%
2019-12-3171.61%-44.32%--
2018-12-3164.66%-84.98%--
2017-12-3164.49%-118.09%-77.91%-

Investor relations

Next earnings report

Next confirmed report
Nov 19, 2026

Past earnings dates

ReportedFiscal periodEPS estimate
2026-09-10Jun 2026-
2026-06-09Mar 2026-
2026-03-12Dec 2025-
2025-11-20Sep 2025-
2025-09-08Jun 2025-
2025-06-06Mar 2025-
2025-03-25Dec 2024-
2024-12-03Sep 2024-

Filings and sources

Company website
brbiotech.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · Natera, Inc. (NTRA) · Agilent Technologies, Inc. (A) · IQVIA Holdings Inc. (IQV) · IDEXX Laboratories Inc (IDXX) · Waters Corp (WAT) · Illumina, Inc. (ILMN)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades